H.C. Wainwright reiterates Cytokinetics (CYTK) as a top pick after Bristol-Myers (BMY) announced that the Phase 3 ODYSSEY-HCM clinical trial evaluating mavacamten in non-obstructive hypertrophic cardiomyopathy patients did not meet its dual primary endpoints. The firm believes Cytokinetics’ aficamten has exhibited a promising benefit risk profile, positioning itself as a potential first-in-class treatment. It keeps a Buy rating on the shares with a $120 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics price target lowered to $54 from $62 at BofA
- Cautious Outlook on Cytokinetics Amid CMI Market Challenges and Strategic Concerns
- Citi adds two, removes two from North America Focus List
- Optimistic Buy Rating on Cytokinetics Driven by Promising Aficamten Trial Outcomes
- Biotech Alert: Searches spiking for these stocks today